





Supplementary figure 1: (a) Expression of selected differentially expressed genes (DEGs) for ECM gel treatment with respect to PBS controls genes are presented as log ratio ($\log_2FC$). (b) Expression of selected shared genes (apoptosis process) between ECM gel treatment and PBS controls with respect to uninjured controls are presented as log ratio ($\log_2FC$). (c) Selected shared differentially expressed proteins (mitochondrial oxidative metabolism, apoptosis process) for ECM gel treatment with respect to PBS controls genes (3DPI and 14 DPI) are presented as log ratio ($\log_2FC$).



Supplementary figure 2: (a) Top pathways given by Ingenuity Pathway Analysis (IPA) based on differentially expressed genes (cut off for DEGs was $FDR < 0.05$ and $|\log_2FC| > 1.5$) compared to uninjured muscle. (b) Top pathways given by IPA based on differentially expressed proteins (cut off for DEPs was $p < 0.05$ and $|\log_2FC| > 1$) compared to uninjured muscle (EAJs = epithelial adherens junctions).